Total Payments
$12,316
2024 Payments
$170.86
Companies
14
Transactions
58
Medicare Patients
2,861
Medicare Billing
$334,603
Payment Breakdown by Category
Research$7,684 (62.4%)
Travel$3,042 (24.7%)
Food & Beverage$1,440 (11.7%)
Education$149.86 (1.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $7,684 | 11 | 62.4% |
| Travel and Lodging | $3,042 | 11 | 24.7% |
| Food and Beverage | $1,440 | 33 | 11.7% |
| Education | $149.86 | 3 | 1.2% |
Payments by Type
Research
$7,684
11 transactions
General
$4,632
47 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme Corporation | $5,005 | 3 | $0 (2018) |
| INTUITIVE SURGICAL, INC. | $3,583 | 29 | $0 (2024) |
| F. Hoffmann-La Roche AG | $2,679 | 8 | $0 (2021) |
| GlaxoSmithKline, LLC. | $185.78 | 2 | $0 (2023) |
| TESARO, Inc. | $171.07 | 4 | $0 (2019) |
| Foundation Medicine, Inc. | $129.93 | 2 | $0 (2023) |
| Gen-Probe Sales & Service, Inc. | $122.00 | 1 | $0 (2022) |
| Baxter Healthcare | $109.13 | 3 | $0 (2023) |
| Seagen Inc. | $96.00 | 1 | $0 (2023) |
| Genentech USA, Inc. | $90.69 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $170.86 | 7 | INTUITIVE SURGICAL, INC. ($170.86) |
| 2023 | $616.88 | 10 | Foundation Medicine, Inc. ($129.93) |
| 2022 | $246.03 | 3 | Gen-Probe Sales & Service, Inc. ($122.00) |
| 2021 | $2,154 | 7 | F. Hoffmann-La Roche AG ($2,137) |
| 2020 | $623.37 | 5 | F. Hoffmann-La Roche AG ($541.83) |
| 2019 | $179.99 | 7 | Intuitive Surgical, Inc. ($165.49) |
| 2018 | $8,077 | 15 | Merck Sharp & Dohme Corporation ($5,005) |
| 2017 | $247.61 | 4 | TESARO, Inc. ($120.00) |
All Payment Transactions
58 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | INTUITIVE SURGICAL, INC. | Da Vinci Surgical System (Device) | Travel and Lodging | In-kind items and services | $6.00 | General |
| Category: SURGERY | ||||||
| 12/03/2024 | INTUITIVE SURGICAL, INC. | Da Vinci Surgical System (Device) | Food and Beverage | In-kind items and services | $4.75 | General |
| Category: SURGERY | ||||||
| 11/12/2024 | INTUITIVE SURGICAL, INC. | Da Vinci Surgical System (Device) | Education | In-kind items and services | $71.37 | General |
| Category: SURGERY | ||||||
| 09/17/2024 | INTUITIVE SURGICAL, INC. | Da Vinci Surgical System (Device) | Education | In-kind items and services | $52.63 | General |
| Category: SURGERY | ||||||
| 08/06/2024 | INTUITIVE SURGICAL, INC. | Da Vinci Surgical System (Device) | Education | In-kind items and services | $25.86 | General |
| Category: SURGERY | ||||||
| 08/06/2024 | INTUITIVE SURGICAL, INC. | Da Vinci Surgical System (Device) | Food and Beverage | In-kind items and services | $6.00 | General |
| Category: SURGERY | ||||||
| 07/09/2024 | INTUITIVE SURGICAL, INC. | Da Vinci Surgical System (Device) | Food and Beverage | In-kind items and services | $4.25 | General |
| Category: SURGERY | ||||||
| 11/16/2023 | Myriad Genetic Laboratories, Inc. | MYCHOICE CDX (Device) | Food and Beverage | In-kind items and services | $79.67 | General |
| Category: ONCOLOGY | ||||||
| 10/05/2023 | GlaxoSmithKline, LLC. | JEMPERLI (Biological) | Food and Beverage | In-kind items and services | $92.55 | General |
| Category: ONCOLOGY | ||||||
| 08/11/2023 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $28.19 | General |
| Category: Oncology | ||||||
| 07/21/2023 | Foundation Medicine, Inc. | FOUNDATIONONE LIQUID CDX | Food and Beverage | In-kind items and services | $10.41 | General |
| 06/06/2023 | Intuitive Surgical, Inc. | Da Vinci Surgical System (Device) | Food and Beverage | In-kind items and services | $74.09 | General |
| Category: SURGERY | ||||||
| 05/25/2023 | Foundation Medicine, Inc. | FOUNDATIONONE LIQUID CDX | Food and Beverage | In-kind items and services | $119.52 | General |
| 04/27/2023 | Baxter Healthcare | TISSEEL (Device) | Food and Beverage | In-kind items and services | $58.33 | General |
| Category: Surgical Care | ||||||
| 04/13/2023 | Seagen Inc. | TIVDAK (Biological) | Food and Beverage | In-kind items and services | $96.00 | General |
| Category: Oncology | ||||||
| 03/14/2023 | Intuitive Surgical, Inc. | Da Vinci Surgical System (Device) | Food and Beverage | In-kind items and services | $38.12 | General |
| Category: SURGERY | ||||||
| 01/16/2023 | Baxter Healthcare | FLOSEAL (Device) | Food and Beverage | In-kind items and services | $20.00 | General |
| Category: Surgical Care | ||||||
| 10/20/2022 | Baxter Healthcare | ADEPT (Device) | Food and Beverage | In-kind items and services | $30.80 | General |
| Category: Surgical Care | ||||||
| 08/25/2022 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $93.23 | General |
| Category: ONCOLOGY | ||||||
| 04/14/2022 | Gen-Probe Sales & Service, Inc. | APTIMA (Device) | Food and Beverage | In-kind items and services | $122.00 | General |
| Category: Diagnostics | ||||||
| 03/31/2021 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | — | In-kind items and services | $630.78 | Research |
| Study: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER • Category: BioOncology | ||||||
| 03/31/2021 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | — | In-kind items and services | $434.20 | Research |
| Study: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER • Category: BioOncology | ||||||
| 03/31/2021 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | — | In-kind items and services | $426.64 | Research |
| Study: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER • Category: BioOncology | ||||||
| 03/31/2021 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | — | In-kind items and services | $254.13 | Research |
| Study: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER • Category: BioOncology | ||||||
| 03/31/2021 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | — | In-kind items and services | $206.85 | Research |
| Study: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER • Category: BioOncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Pembrolizumab Versus Treatment of Physician s Choice in Subjects with Advanced Endometrial Cancer | Merck Sharp & Dohme Corporation | $5,005 | 3 |
| A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER | F. Hoffmann-La Roche AG | $2,310 | 7 |
| A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | F. Hoffmann-La Roche AG | $369.38 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 20 | 546 | 5,221 | $418,086 | $61,699 |
| 2022 | 26 | 781 | 24,004 | $912,336 | $105,467 |
| 2021 | 21 | 701 | 10,130 | $495,802 | $82,527 |
| 2020 | 28 | 833 | 21,911 | $679,508 | $84,910 |
Total Patients
2,861
Total Services
61,266
Medicare Billing
$334,603
Procedure Codes
95
All Medicare Procedures & Services
95 procedure records from CMS Medicare Utilization — Page 3 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 43 | 43 | $21,887 | $5,385 | 24.6% |
| 86304 | Immunologic analysis for detection of tumor antigen, quantitative; ca 125 | Office | 2021 | 51 | 189 | $23,436 | $3,877 | 16.5% |
| 96417 | Infusion of different chemotherapy drug or substance into a vein up to 1 hour | Office | 2021 | 19 | 45 | $15,030 | $2,470 | 16.4% |
| 96367 | Infusion into a vein for therapy prevention or diagnosis additional sequential infusion up to 1 hour | Office | 2021 | 22 | 107 | $16,264 | $2,388 | 14.7% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2021 | 49 | 218 | $13,516 | $2,274 | 16.8% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2021 | 57 | 231 | $8,085 | $1,770 | 21.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 15 | 17 | $5,610 | $1,424 | 25.4% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 30 | 38 | $5,168 | $1,212 | 23.4% |
| 96415 | Infusion of chemotherapy into a vein | Office | 2021 | 15 | 48 | $7,488 | $1,157 | 15.4% |
| 96375 | Injection of different drug or substance into a vein for therapy, diagnosis, or prevention | Office | 2021 | 28 | 87 | $9,135 | $1,063 | 11.6% |
| J9267 | Injection, paclitaxel, 1 mg | Office | 2021 | 13 | 7,254 | $14,508 | $874.20 | 6.0% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2021 | 24 | 410 | $50,020 | $733.68 | 1.5% |
| J9045 | Injection, carboplatin, 50 mg | Office | 2021 | 19 | 337 | $101,100 | $702.13 | 0.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 68 | 228 | $4,332 | $675.00 | 15.6% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2021 | 16 | 390 | $390.00 | $45.38 | 11.6% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2021 | 19 | 40 | $280.00 | $28.04 | 10.0% |
| J3490 | Unclassified drugs | Office | 2021 | 17 | 37 | $333.00 | $24.65 | 7.4% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2020 | 20 | 94 | $15,040 | $14,990 | 99.7% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2020 | 44 | 121 | $83,006 | $13,031 | 15.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 114 | 177 | $39,825 | $8,551 | 21.5% |
| 86304 | Immunologic analysis for detection of tumor antigen | Office | 2020 | 62 | 245 | $30,380 | $5,011 | 16.5% |
| 96367 | Infusion into a vein for therapy prevention or diagnosis additional sequential infusion up to 1 hour | Office | 2020 | 29 | 197 | $29,944 | $4,604 | 15.4% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2020 | 18 | 26 | $26,936 | $4,588 | 17.0% |
| J1453 | Injection, fosaprepitant, 1 mg | Office | 2020 | 13 | 4,500 | $27,000 | $4,465 | 16.5% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 34 | 34 | $17,306 | $4,023 | 23.2% |
About Dr. Charles Anderson, M.D
Dr. Charles Anderson, M.D is a Obstetrics & Gynecology healthcare provider based in Eugene, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/17/2008. The National Provider Identifier (NPI) number assigned to this provider is 1215191259.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Charles Anderson, M.D has received a total of $12,316 in payments from pharmaceutical and medical device companies, with $170.86 received in 2024. These payments were reported across 58 transactions from 14 companies. The most common payment nature is "" ($7,684).
As a Medicare-enrolled provider, Anderson has provided services to 2,861 Medicare beneficiaries, totaling 61,266 services with total Medicare billing of $334,603. Data is available for 4 years (2020–2023), covering 95 distinct procedure/service records.
Ad
Practice Information
- Specialty Obstetrics & Gynecology
- Other Specialties Gynecologic Oncology
- Location Eugene, OR
- Active Since 07/17/2008
- Last Updated 08/05/2021
- Taxonomy Code 207V00000X
- Entity Type Individual
- NPI Number 1215191259
Products in Payments
- KEYTRUDA (Biological) $5,005
- Da Vinci Surgical System (Device) $3,583
- TECENTRIQ (Biological) $2,137
- Tecentriq (Biological) $541.83
- ZEJULA (Drug) $264.30
- APTIMA (Device) $122.00
- TIVDAK (Biological) $96.00
- JEMPERLI (Biological) $92.55
- Avastin (Biological) $90.69
- MYCHOICE CDX (Device) $79.67
- TISSEEL (Device) $58.33
- ADEPT (Device) $30.80
- Xtandi (Drug) $28.19
- FLOSEAL (Device) $20.00
- LYNPARZA (Drug) $16.31
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Obstetrics & Gynecology Doctors in Eugene
Amy Mccarthy, Md, MD
Obstetrics & Gynecology — Payments: $6,796
Obstetrics & Gynecology $6,796
Dr. Elizabeth Mccorkle, Md, MD
Obstetrics & Gynecology — Payments: $6,034
Obstetrics & Gynecology $6,034
Dr. Johanna Higdon, Md, MD
Obstetrics & Gynecology — Payments: $4,776
Obstetrics & Gynecology $4,776
Richard Lee, Md, MD
Obstetrics & Gynecology — Payments: $1,244
Obstetrics & Gynecology $1,244
Brian Wakefield, M.d, M.D
Obstetrics & Gynecology — Payments: $1,142
Obstetrics & Gynecology $1,142
Dr. Sara Gerhards, Md, MD
Obstetrics & Gynecology — Payments: $1,119
Obstetrics & Gynecology $1,119